<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Oct. 2, 2020 (HealthDay News) — For patients with COVID-19 receiving extracorporeal membrane oxygenation (ECMO) support, mortality is below 40 percent, according to a study published online Sept. 25 in The Lancet<\/i>.<\/p>\n
Ryan P. Barbaro, M.D., from the University of Michigan in Ann Arbor, and colleagues characterized epidemiology, hospital course, and outcomes for patients aged 16 years or older with COVID-19 who received ECMO support initiated between Jan. 16 and May 1, 2020. Data were included for 1,035 patients with COVID-19.<\/p>\n
The researchers found that 6 percent of the patients remained hospitalized; 30, 10, and 17 percent were discharged home or to an acute rehabilitation center, to a long-term acute care center or unspecified location, and to another hospital, respectively; and 37 percent died. Ninety-days after initiation of ECMO, the estimated cumulative incidence of in-hospital mortality was 37.4 percent. In patients with a final disposition of death or hospital discharge, mortality was 39 percent. There was an independent association observed between use of ECMO for circulatory support and higher in-hospital mortality (hazard ratio, 1.89). The estimated cumulative incidence of in-hospital mortality 90 days after ECMO initiation was 38.0 percent in the subset of patients with COVID-19 receiving respiratory (venovenous) ECMO and characterized as having acute respiratory distress syndrome.<\/p>\n
“Our results are also consistent with previously reported survival rates in acute hypoxemic respiratory failure, supporting current recommendations that centers experienced in ECMO should consider its use in refractory COVID-19-related respiratory failure,” the authors write.<\/p>\n
Several authors disclosed financial ties to the biopharmaceutical industry.<\/p>\n